An Idaho representative seeks to shield execution team members, and grant greater power to the state prison director over ...

Watch, the IV safety company, has partnered with Aon, a leading global insurance broker and risk consultant, to quantify the clinical and financial impact of severe IV infiltration and extravasation ...

Q4 2025 earnings call: nimacimab + semaglutide data, higher-dose expansion, Halozyme SC plans, 2026 catalysts—read now.

PM Modi blasted the prior 'AAPda' regime for a decade of stalled progress—delaying Metro Phase-IV for politics, snubbing ...

NHRA Pro Stock star and multi-time Factory Stock Showdown world champion Aaron Stanfield added another significant ...

Becton, Dickinson and Company ( BDX) Barclays 28th Annual Global Healthcare Conference March 10, 2026 8:30 AM EDT Good morning. Thanks very much for joining us. Very pleased today to have with us Tom ...

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...

A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.

Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...

Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...

The Hematologic Malignancies Market is projected to grow from USD 72,200.85 million in 2024 to USD 128,481.41 million by 2032, registering a CAGR of 7.47% during 2024--2032. Growth is underpinned by ...